@article{TAU11491,
author = {Wesley Baas and Tobias S. Köhler},
title = {Testosterone replacement therapy and voiding dysfunction},
journal = {Translational Andrology and Urology},
volume = {5},
number = {6},
year = {2016},
keywords = {},
abstract = {Testosterone replacement therapy (TRT) represents an increasing popular treatment option for men with late-onset hypogonadism (LOH). Because of unsubstantiated beliefs of testosterone’s effect on the prostate, the FDA has recently placed a warning on testosterone products, stating that TRT may worsen benign prostatic hyperplasia (BPH). Within this review article we have demonstrated the current understanding of the physiology of testosterone and its relationship with prostatic and lower urinary tract physiology. The current evidence suggests that not only does TRT not worsen lower urinary tract symptoms (LUTS), but that hypogonadism itself is an important risk factor for LUTS/BPH.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/11491}
}